

Update

22 November 2011

CELL LINE DEVELOPMENT

After an extensive tendering process, Paranta has awarded a contract to a major US company for development of a recombinant human follistatin cell line to support future GMP production.

Transfer of the follistatin cell line to a GMP qualified contract manufacturing organization is expected to commence in mid 2012. Paranta expects to finalize selection of its GMP contract manufacturing partner early in the second quarter of 2012.

Ross Barrow
Chief Executive Officer

Paranta Biosystems Limited
A.C.N. 141 027 107